Thomas Jefferson University

Jefferson Digital Commons
Rothman Institute Faculty Papers

Rothman Institute

9-5-2022

Gut Permeability May Be Associated With Periprosthetic Joint
Infection After Total Hip and Knee Arthroplasty
Emanuele Chisari
Jeongeun Cho
Marjan Wouthuyzen-Bakker
Javad Parvizi

Follow this and additional works at: https://jdc.jefferson.edu/rothman_institute
Part of the Medical Microbiology Commons, and the Orthopedics Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Rothman Institute Faculty Papers by an authorized administrator of the Jefferson Digital
Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

www.nature.com/scientificreports

OPEN

Gut permeability may be
associated with periprosthetic joint
infection after total hip and knee
arthroplasty
Emanuele Chisari1,2*, Jeongeun Cho1, Marjan Wouthuyzen‑Bakker2 & Javad Parvizi1
A growing number of recent investigations on the human genome, gut microbiome, and proteomics
suggests that the loss of mucosal barrier function, particularly in the gastrointestinal tract, may
substantially affect antigen trafficking, ultimately influencing the close bidirectional interaction
between the gut microbiome and the immune system. This cross-talk is highly influential in shaping
the host immune system function and ultimately affecting the outcome of interventions. We
hypothesized that the loss of mucosal barrier in the gut may be associatedto acute and chronic
periprosthetic joint infections (PJI). Zonulin, soluble CD14 (sCD14), and lipopolysaccharide (LPS) were
tested in plasma as part of a prospective cohort study of patients undergoing primary arthroplasty
or revision arthroplasty because of an aseptic failure or PJI (as defined by the 2018 criteria). All blood
samples were collected before antibiotic administration. Samples were tested using commercially
available enzyme-linked immunosorbent assays as markers for gut permeability. A total of 134
patients were included in the study of which 44 patients had PJI (30 chronic and 14 acute), and the
remaining 90 patients were categorized as non-infected that included 64 patients revised for aseptic
failure, and 26 patients undergoing primary total joint arthroplasty. Both Zonulin (7.642 ± 6.077 ng/mL
vs 4.560 ± 3.833 ng/mL; p < 0.001) and sCD14 levels (555.721 ± 216.659 ng/mL vs 396.872 ± 247.920 ng/
mL; p = 0.003) were significantly elevated in the PJI group compared to non-infected cases. Higher
levels of Zonulin were found in acute infections compared to chronic PJI (11.595 ± 6.722 ng/mL
vs. 5.798 ± 4.841 ng/mL; p = 0.005). This prospective study reveals a possible link between gut
permeability and the ‘gut-immune-joint axis’ in PJI. If this association continues to be borne out with
a larger cohort and more in-depth analysis, it will have a clinically significant implication in managing
patients with PJI. It may be that in addition to the administration of antimicrobials, patients with PJI
and other orthopaedic infections may benefit from administration of gastrointestinal modulators such
as pro and prebiotics.
Prior studies investigating the etiopathogenesis of surgical site infection (SSI) suggested three main avenue for
infection to occur: local contamination occurring during surgery, hematogenous translocation of bacteria during
concomitant bacteraemia, and contamination from adjacent infected tissues by the progression of the infective
process1. While most of the research on SSI focused on minimizing any source of pathogens at the time of the
surgery2,3, emerging evidence demonstrates how acute and chronic SSI can emerge more often from endogenous
sources of microorganisms such as the gastrointestinal system, especially in the context of unbalanced gut flora,
‘dysbiosis’, and impaired gut p
 ermeability4–8.
One of the most common organisms causing periprosthetic joint infections (PJI), namely Staphylococcus
aureus has been shown to be able to translocate from the gut to prosthetic joints or the surgical site in preclinical
models of SSI and P
 JI9,10. An emerging theory, the ’Trojan Horse’ hypothesis, assumes that the translocation process is not necessarily mediated by blood only (i.e. bacteremia), but also by blood cells such as neutrophils11–13 and
macrophages14 that act as a" Trojan Horse" transporting pathogens between various sites. Mechanistic evidence
supports a close interaction between pathogens like S. aureus and the immune s ystem15, but confirmation of this
phenomenon in vivo remains. Cohort studies, evaluating populations with high prevalence of gut microbiome
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dysbiosis, such as patients with obesity, reported higher risk of enterococcus and proteus infections, which are
common gut c ommensals16.
Gut epithelium intercellular tight junctions (TJs) regulate paracellular antigen trafficking and microbiomeimmune system interaction. TJs are highly dynamic structures that serve critical functions to maintain integrity
of the intestinal epithelium under both physiological and pathological circumstances 17–19. Despite significant
progress in our knowledge on the composition and function of the intercellular TJ, the mechanisms by which they
are regulated remains largely unknown. One of the breakthroughs in understanding the role of gut permeability
in health and disease has been the discovery of zonulin, the only physiologic intestinal permeability modulator
described so f ar20,21. Zonulin has been used as a marker for increased intestinal permeability and is associated
with soluble CD14 (sCD14) and lipopolysaccharide (LPS), other common markers of inflammation and bacterial translocations22. Thus, in combinations these markers allow for study of gut permeabilitym and can act as a
proxy for gut microbiome and dysbiosis.
The hypothesis of the current study was that levels of Zonulin, LPS and sCD14, known indicators of gut
permeability, will be elevated in patients with acute and chronic PJI indicating that some degree of gut impaired
barrier function may be at associated to PJI.

Materials and methods

After approval by the institutional review board of Thomas Jefferson University, and registration of the prospective study in clinicaltrial.gov (NCT04666519), patients scheduled for joint arthroplasty were screened for
eligibility. Informed consent was obtained from all patients, and the study was conducted in accordance with
relevant guidelines and regulations. Patients with the diagnosis of osteoarthritis undergoing primary total joint
arthroplasty, and patients undergoing revision arthroplasty for aseptic failures or periprosthetic joint infection
(PJI), as determined by the 2018 international consensus meeting (ICM) definition, were i ncluded23. Management
of the patients was done according to standard of care. For revision patients, culture are collected with aseptic
technique from multiple areas of the surgical site and then cultured according to good laboratory practices.
Patients with prior history of joint infection, diagnosis of autoimmune diseases, inflammatory bowel disease,
irritable bowel syndrome and otherwise unspecified chronic gut issues were excluded. Patients being included in
the study were consented prior to obtaining blood samples. A total of 155 patients were screened and approached
for inclusion, among whom 134 patients agreed to participate between January and November 2021. The blood
samples were obtained by venepuncture and transported in citrate buffer vacutainers to the laboratory within a
40-min window. Once transported, samples were processed, split in cryovials and snap-frozen at − 80C freezer.
Plasma samples were tested using validated ELISA assays for sCD14(Invitrogen sCD14 Human ELISA Kit),
LPS (ENDONEXT™ EndoZyme® II—Recombinant Factor C (rFC) Endotoxin Detection Assay), and Zonulin
(Human zonulin ELISA kit, Cusabio). The assay was performed in agreement with manufacturer instruction.

Statistical analysis. Based on a medium effect size as a minimally clinical significant result (Cohen’s

d = 0.5), a beta of 0.2, an alpha of 0.05, we determined that 128 patients were needed.
The data was tested for normality with the Shapiro–Wilk test. Data was then analyzed with parametric and
non-parametric tests to answer study questions. Student t-test, Mann–Whitney test, ANOVA, and Kruskal–Wallis were used for continuous variables. A Chi-squared and Fischer exact test were used for categorical variables.
To allow for easy readability, the figures were magnified. Pearson correlation test was used to draw correlation
amont the continues variables normally distributed. Continuous variables were reported as mean and standard
deviation or median and interquartile range depending on normal or not normal distribution.Full figure and
data is available as Supplementary Material. Statistical analysis was performed using open-source software JASP,
JASP Team (2020). JASP (Version 0.14.1)[Computer software].

Results

Among the cohort of 134 (46% female) patients, with a mean age of 67.7 years (range, 36 to 92) and a mean BMI
30.6 ± 7.0 (Table 1), 44 patients underwent revision for PJI (30 chronic and 14 acute infections), 90 patients were
classified as aseptic (26 primaries and 64 aseptic revisions).
No difference in the levels of LPS, sCD14 or Zonulin were retrieved between GRAM+ and GRAM− bacteria.
Both Zonulin and sCD14, but not LPS, were found to be significantly elevated in the PJI group 7.642 ± 6.077 ng/
mL and 555 ± 216 ng/mL, compared to non-infected cases (p < 0.001; p = 0.003) (Fig. 1).
For PJI cases, intraoperative-sampled tissue culture for bacterial identification was performed. Overall, out
of the 44, 24 had culture positive, 17 were bacterial monomicrobial (14 GRAM +) 5 were polymicrobial, 1 was
positive for fungi (Candida Glabrata) and one for not specified acid-fast positive bacilli (Supplementary material).
When only patients categorized as PJI were evaluated, higher levels of Zonulin were found in acute infections
compared to chronic (10.7 ± 6.2 ng/mL vs 5.8 ± 4.8 ng/mL; p = 0.005) (Fig. 2).
When patients were allocated to the four different arms designed by this study enrollment plan, LPS and
Zonulin showed increased levels for primaries, aseptic revisions, chronic and acute infections progressively
(p < 0.001) (Table 2). Interestingly, sCD14 levels were significantly higher in primaries compared to aseptic
revisions (Fig. 3).
No significant difference in the levels of Zonulin, sCD14 and LPS were found between males and females or
hip and knees. Out of concern of correlation with acute-phase proteins, Zonulin and C-reactive protein (CRP)
were investigated with no significant findings (Fig. 4).
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Variable

Full cohort

ICM Negative

ICM positive

N = 134

N = 90

N = 44

Gender
Female

62 (46.3%)

41 (45.6%)

21 (47.7%)

Male

72 (53.7%)

49 (54.4%)

23(52.3%)

Age

67.7 (10.3)

67.7 (10.3)

67.614 (10.5)

Body mass index (Kg/m2)

30.6 (7.0)

30.6 (6.98)

30.8 (7.11)

Joint
Hip

66 (49.3%)

47 (52.2%)

`19 (43.2%)

Knee

68 (50.7%)

43 (47.8%)

25 (56.8%)

Table 1.  Baseline characteristics of the cohort. ICM: International Consensus meeting definition for
periprosthetic joint infection. For gender and joint variables, absolute number of subjects and rate as % was
reported. For all other variables mean and standard deviation were reported.

Figure 1.  Descriptive plots of gut permeability biomarkers (CD14, Zonulin, LPS) are provided.Data were
reported as mean and standard deviation. LPS: Lipopolysaccharide. ICM: International Consensus Meeting.
**:p < 0.05; ***:p < 0.001. If data was not flagged (*), the comparison was not found significant.

Discussion

Gut health and resident microbiome have been the focus of major research efforts in recent years around the
globe. The emerging evidence suggests that there is a close connection between microbiome and overall host
immunity and diseases24–27. The gut microbiome in particular has been found to modulate numerous diseases28–30.
Studies have shown that patients with inflammatory bowel disease (IBD) for example, have a disturbed gut microbiome that could explicate the higher rate of systemic infections in these patients31. In a retrospective study from
our institution, we also demonstrated that patients with IBD were at higher risk of developing periprosthetic
joint infection (PJI) of hip and k nee30. The prior findings was the impetus for the current study seeking further
evidence for the presence of potential relationship between gut dysbiosis and PJI.
The current clinical study, first of its kind to our knowledge, adds weigh to prior pre-clinical studies demonstrating a relationship between gut dysbiosis and PJI in animal models9,15,32. We realize that surgical site infections
such as PJI are complex diseases in which a vast number of etiological factors are in p
 lay17,33–35. We also recognize
that a combination of environmental and genetic factors contribute to the development of any diseases such as
PJI1. It is also clear that immune response plays a critical role in pathophysiology of any diseases, particularly
infections36,37. Relying on the available evidence, we hypothesized that the gut microbiome and permeability
have a role in shaping immune response to external pathogens as previously shown in other fi
 elds17,37,38. The
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Figure 2.  Levels of Zonulin based on the timing of the infection. **: p < 0.05.

Variable

Primary arthroplasty

Aseptic revision

Chronic PJI

Acute PJI

N = 26

N = 60

N = 30

N = 14

Zonulin ng/mL

3.980 (4.5)

4.811 (3.4)

5.798 (4.8)

11.595 (6.7)

CD14 ng/mL

671.424 (115.3)

289.625 (197.9)

534.781 (184.2)

600.591 (276.3)

LPS u/mL

1.95 (1.5)

2.45 (0.89)

3.19 (4.8)

3.53 (3.2)

Table 2.  Plasma gut permeability markers based on arm allocation. Data was presented as mean and standard
deviation. PJI: periprosthetic joint infection. PJI definition was based on 2018 international consensus meeting
definition.

Figure 3.  Descriptive plots based on arm allocation. Data are reported as mean and standard error. 0:
primaries; 1: aseptic revisions; 2: Chronic PJI; 3:acute PJI.
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Figure 4.  Correlation plot between Zonulin and C-reactive protein for infected patients.

preliminary, yet concrete, evidence generated by the current study brings to light the role that gut microbiome
may play a role in PJI. As a matter of fact, the lack of association between microbiological profile of the infection and the levels of the gut permeability biomarker, make evident that their role is mostly associate with what
happens in the gut microbiome and not in the local site of infection. We speculate that this association is due
to the role of the human gut microbiome in shaping both adaptive and innate immune responses to external
pathogens, that has been seen in other fi
 elds24,25,27.
An interesting, and somewhat surprising, findings of this study was that the level of sCD14 was lower in
patients undergoing revision for aseptic failure than patients receiving primary joint replacement. While we
cannot fully explain this finding, we speculate that the different behaviour of this biomarker is related to its physiological function. sCD14 is a marker of monocyte activation that acts as acute phase protein and its levels under
the influence of LPS and other bacterial by-products39,40. Patients undergoing aseptic revision have been subject
of two microbiome depleting stressors: antibiotic therapy and at least one previous surgery. Thus, it is possible that
patients with gut imbalance (high level of Zonulin), but low biomass, can have a similar level of sCD14. To prove
or refute such speculation metagenomic analysis of the gut microbiome in a longitudinal study will be needed.
Although the current study was prospectively designed, its exploratory nature is not exempt from limitations.
First, this study is based on a single-center patient population and its generalizability may be limited. Although
our cohort size was deemed to be adequate, based on power analysis, some differences in the level of biomarkers
could be subject to type 2 statistical error, especially for small effect size interactions. Additionally, all the markers
examined are proteins that behave as acute phase reactants, and their level have been shown to correlate with
other biomarkers of i nflammation41,42. As such, the absence of metagenomic data on this cohort does not allow
definite conclusion on their pathophysiology. However, for the infected cohort, we did not find any correlation
between Zonulin and CRP, a known biomarker of inflammation (Fig. 4). Finally, the biomarkers examined are
indirect measure of gut epithelial barrier integrity, and direct measurement of gut dysbiosis and inflammation
would require invasive testing which we did not perform. However, this approach seems scientifically reasonable
as many prior studies have relied on indirect measure of gut dysbiosis to implicate its relationship with various
diseases17,19,43–48.
In conclusion, the findings of this prospective ongoing study are interesting as a possible link between gut permeability, the ‘gut-immune-joint axis’, and PJI is being proposed. These findings are clinically relevant beseeching
our attention to the role that gut modulators such as probiotics and prebiotics may play in the management of
patients with PJI, who are routinely subjected to prolonged courses of antimicrobials. Future studies exploring
the ‘gut-immune-joint axis’ and the role that modulators of gastrointestinal may play are needed.
Received: 2 December 2021; Accepted: 23 August 2022
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